Eric Ho

Managed care titans CVS Caremark and Express Scripts are undertaking major changes to their preferred drug formularies that may significantly impact a number of well-known diabetes medications and manufacturers.

In a familiar echo for pain medications in the past, state attorneys across the US have submitted new concerns over Zogenix and Zohydro ER that may seriously dampen its success or influence the FDA to recall Zohydro's approval entirely...

A number of well-known GlaxoSmithKline drugs, including one major blockbuster, will no longer be covered by the largest pharmacy benefit manager in the U.S. beginning Jan. 1.

The tide has turned dramatically for in-store care clinics at major pharmacy retailers over the last few years. While previously growth for these services had stalled due to lack of dialogue between providers, new waves of partnerships for CVS, Walgreen, and Rite Aid are changing the game for convenient care.

Big names like GlaxoSmithKline, Arena, VIVUS, and Orexigen are probably well-known among obesity market watchers, but this less publicized company out of Massachusetts is poised to change the landscape in coming years.

The oft-overlooked home infusion and alternative site infusion market represents a huge opportunity for CVS Caremark with its recent acquisition of leading infusion provider Coram Specialty Infusion Services.

While Arena Pharmaceuticals' Belviq may need time to gain traction, it may have many of the right pieces in the right places to realize its long-term prospects

Arena Pharmaceuticals' Belviq continues to stall despite huge early expectations. Let's take a look at the current barriers and potential future success for Belviq...

Recent decisions by the Food and Drug Administration poses new questions about Sarepta Therapeutics, eteplirsen, and the future of DMD treatment.

Recent developments in controlled substance rules may help Zogenix's extended-release hydrocodone product to market when it will need all the help it can get.

Walgreen's new partnership could change the way we think of pharmacies.

A second opinion on the recent Keryx rush.

Afrezza could be a blockbuster, but will physicians wait and see?